Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Search results
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Pancake Day or Shrove Tuesday, which in 2025 falls on Tuesday 4 March, could be a great opportunity to fundraise for Retina UK, whilst having fun and eating lots of yummy pancakes!
If you could use the long bank holiday weekend to fundraise for Retina UK, we would love to hear from you!
Back for 2023, the virtual TCS London Marathon lets you join our team close to home and get your marathon medal!
Volunteers are highly valued members of the Retina UK team and essential to our ability to achieve our vision of a world where all those affected by inherited retinal conditions are able to live a fulfilling life.
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
There are many ongoing clinical and laboratory studies around the world, exploring innovative approaches to treating inherited sight loss.
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Are you affected by inherited sight loss? We are here to help.